Related Experiment Video
Updated: May 16, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Effects of siRNA‑mediated Cdc2 silencing on MG63 cell proliferation and apoptosis
Xiang-Yong Que1, Yi Li, Yu Han
1Department of Orthopedics, Renhe Hospital of Three Gorges University, Yichang 443001, P.R. China.
Abstract:
The present study aimed to determine the effect of small interfering RNA (siRNA)‑induced inhibition of cyclin‑dependent kinase 2 (Cdc2) expression on osteosarcoma MG63 cell proliferation and apoptosis. An siRNA expression plasmid, psilencer 2.1‑U6/Cdc2, targeting the Cdc2 gene, and a control psilencer 2.1‑U6/Scramble plasmid were constructed and transfected into MG63 cells using liposomes. Cdc2 expression in the MG63 cells was investigated by western blot analysis and real‑time polymerase chain reaction. Cell morphology was also examined. The effects of psilencer 2.1‑U6/Cdc2 on MG63 cell proliferation and the cell cycle were detected via MTT and flow cytometry, respectively. Expression levels of apoptosis‑related molecules, B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑associated X (Bax) were determined by western blot analysis. MG63 cells stably transfected with the psilencer 2.1‑U6/Cdc2 plasmid (MG63‑siRNA/Cdc2) and negative control cells, MG63‑siRNA/Scramble, were successfully obtained. The silencing efficiencies of the Cdc2‑expressing mRNA and protein in MG63‑siRNA/Cdc2 were 86 and 89% of that of the control MG63‑siRNA/Scramble cells, respectively. Interference of Cdc2 expression inhibited MG63 cell proliferation and was demonstrated to significantly increase and decrease cells in the G2/M and S phases, respectively. Cdc2 expression silencing had negligible effects on Bcl‑2 and Bax expression in MG63 cells. In conclusion, silencing of Cdc2 expression suppresses proliferation of osteosarcoma MG63 cells but has negligible effects on apoptosis.
Insights
Silencing cyclin-dependent kinase 2 (Cdc2) with siRNA inhibits osteosarcoma cell proliferation by altering the cell cycle. This study found Cdc2 inhibition impacts cell cycle phases but not apoptosis-related molecules.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Osteosarcoma is a prevalent bone cancer.
- Cyclin-dependent kinase 2 (Cdc2) plays a role in cell cycle regulation.
- Targeting Cdc2 may offer a therapeutic strategy for osteosarcoma.
Purpose of the Study:
- To investigate the effect of inhibiting cyclin-dependent kinase 2 (Cdc2) expression on osteosarcoma MG63 cell proliferation and apoptosis.
- To evaluate the efficacy of small interfering RNA (siRNA) in silencing Cdc2 expression in MG63 cells.
Main Methods:
- Osteosarcoma MG63 cells were transfected with siRNA targeting Cdc2 (psilencer 2.1‑U6/Cdc2) or a scrambled control.
- Cdc2 expression was measured using western blot and real-time PCR.
- Cell proliferation, cell cycle, and apoptosis-related molecules (Bcl-2, Bax) were assessed via MTT assay, flow cytometry, and western blot.
Main Results:
- Successful establishment of MG63 cells with silenced Cdc2 expression (MG63‑siRNA/Cdc2).
- Silencing efficiency for Cdc2 mRNA and protein reached 86% and 89%, respectively.
- Inhibition of Cdc2 suppressed MG63 cell proliferation, increased G2/M phase cells, and decreased S phase cells.
- Cdc2 silencing showed negligible impact on Bcl-2 and Bax expression.
Conclusions:
- Silencing Cdc2 expression effectively suppresses osteosarcoma MG63 cell proliferation.
- Cdc2 inhibition influences the cell cycle distribution in osteosarcoma cells.
- Cdc2 silencing does not significantly affect apoptosis-related gene expression in this model.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity

